Dr. Jacques Brown graduated from medical school and completed his residency in Internal Medicine at Laval University. He finished his residency in rheumatology at Université de Sherbrooke before undertaking post-doctoral training in metabolic bone diseases at the INSERM unit in Lyon, France.
He is a clinical researcher at the Centre de recherche du CHU de Québec-Laval University and a clinical professor at the Department of Medicine at Laval University. His major research interest is metabolic bone disorders such as Paget’s disease of bone, and osteoporosis.
Through the characterization of three French-Canadian families with Paget’s disease of bone, he first contributed to the discovery (2001) of the SQSTM1 gene mutations linked to this disease. In collaboration with Dr. Laëtitia Michou, this cohort now contains 43 families, 263 unrelated individuals with Paget’s disease and 298 controls, totalling 1,426 DNA samples with detailed phenotypes. The recruitment of new families and unrelated patients continues to help better identify new genetic factors of Paget’s disease of bone.
Since 1994, he has been a co-principal investigator and Quebec Centre Director on the Canadian Multicentre Osteoporosis Study (CaMOS), an epidemiologic study looking at the prevalence of osteoporosis, as well as the incidence of osteoporotic fractures in a large cohort (9,400 subjects) of the Canadian population. He is the principal investigator of the Recognizing Osteoporosis and its Consequences Programme, a patient health-management programme aimed at evaluating the diagnostic and treatment care gaps for osteoporosis following a fragility fracture in women 50 years of age and over.
He has published over 240 scientific articles in several high-impact journals. He has received several distinctions, including two John G. Haddad Jr. Research Awards from the Paget’s Foundation (2003 and 2005) and the Lindy-Fraser Memorial Award from Osteoporosis Canada (2004) for his work on the clinical practice guidelines of osteoporosis. In 2009, he was knighted to the Ordre National du Québec. More recently, Dr. Brown received the 2017 Distinguished Investigator Award from the Canadian Rheumatology Association for his exceptional contribution to rheumatology in Canada, and the Council of Physicians, Pharmacists, and Dentists of the CHU de Québec has awarded him the Diamant Hommage Héritage for the development and accomplishment of his career which will leave a solid legacy for the future of the institution.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.Journal Article
Clin Ther, 23 (4), pp. 620-6, 2001, ISSN: 0149-2918.
Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids.Journal Article
J Clin Densitom, 4 (4), pp. 363-71, 2001, ISSN: 1094-6950.
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada.Journal Article
Osteoporos Int, 12 (11), pp. 903-8, 2001, ISSN: 0937-941X.
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group.Journal Article
CMAJ, 163 (3), pp. 265-71, 2000, ISSN: 0820-3946.
Improvement of pagetic bone lesions with risedronate treatment: a radiologic study.Journal Article
Bone, 26 (3), pp. 263-7, 2000, ISSN: 8756-3282.
Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.Journal Article
Osteoporos Int, 11 (7), pp. 607-14, 2000, ISSN: 0937-941X.
Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos).Journal Article
Osteoporos Int, 11 (10), pp. 897-904, 2000, ISSN: 0937-941X.
Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos).Journal Article
Osteoporos Int, 11 (8), pp. 680-7, 2000, ISSN: 0937-941X.
Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.Journal Article
Calcif Tissue Int, 64 (2), pp. 93-9, 1999, ISSN: 0171-967X.
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.Journal Article
N Engl J Med, 339 (5), pp. 292-9, 1998, ISSN: 0028-4793.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
Recently finished projects
- Clinical and molecular heterogeneity of Paget's disease of bone., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2013-10-01 to 2018-09-30
- Clinical validity and clinical utility of a screening test for Paget's disease of bone, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-03-01 to 2020-03-31
- Explorations clinique et moléculaire des fractures de stress d'origine génétique, incluant les fractures atypiques des fémurs, Subvention, Fonds de recherche du Québec - Santé, Réseaux thématiques de recherche, from 2018-08-01 to 2019-03-31